Key Points
- CEO Emily Leproust sold 4,573 shares for about $619,000 at $135.40 to cover tax withholding on vested equity awards; she retained 558,187 shares.
- Twist Bioscience’s latest quarter delivered revenue of $118.4 million, above estimates and up 23.2% year over year, but its loss per share of $0.56 was wider than the $0.51 loss analysts expected.
- Analyst sentiment is mixed: the stock has a consensus Hold rating and a $153 average price target, while recent coverage includes both Buy and Sell ratings.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CAO Robert Werner sold 148 shares of the firm's stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $20,039.20. Following the completion of the sale, the chief accounting officer directly owned 42,769 shares of the company's stock, valued at $5,790,922.60. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Twist Bioscience Price Performance
Shares of Twist Bioscience stock opened at $120.61 on Friday. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of -54.33 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock has a 50 day moving average price of $152.00 and a 200-day moving average price of $90.68. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same period in the prior year, the firm posted $0.33 EPS. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. Equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Institutional Trading of Twist Bioscience
Several institutional investors and hedge funds have recently made changes to their positions in TWST. Abacus Wealth Partners LLC lifted its stake in Twist Bioscience by 4.3% in the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company's stock worth $451,000 after acquiring an additional 96 shares during the period. Root Financial Partners LLC purchased a new position in Twist Bioscience during the 3rd quarter valued at about $33,000. GAMMA Investing LLC increased its position in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock valued at $97,000 after purchasing an additional 185 shares during the period. Abel Hall LLC raised its holdings in shares of Twist Bioscience by 3.6% in the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company's stock valued at $1,066,000 after purchasing an additional 191 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Twist Bioscience by 54.9% in the 2nd quarter. Allworth Financial LP now owns 601 shares of the company's stock valued at $62,000 after purchasing an additional 213 shares in the last quarter.
Twist Bioscience News Roundup
Here are the key news stories impacting Twist Bioscience this week:
- Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
- Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
- Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
- Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.
Wall Street Analyst Weigh In
TWST has been the subject of several recent analyst reports. Barclays lifted their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. TD Cowen increased their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Twist Bioscience in a report on Monday, September 21st. Piper Sandler raised their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, August 5th. Finally, Guggenheim lifted their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Hold" and an average price target of $153.00.
Check Out Our Latest Stock Report on TWST
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.
Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
